A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder

Inclusion Criteria: Participants must meet all the following criteria to be included in the trial: * Aged 18 to 85 years inclusive, at Screening * Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR \[if single episode, duration of ≥4 weeks and ≤24 months\] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60. * Depression is of moderate to severe degree at Screening and Baseline, independently confirmed by additional clinical assessments * Participant has been on a stable dose of a single antidepre…